Bupropion/dextromethorphan - Axsome Therapeutics
Alternative Names: AUVELITY; AXS-05; Dextromethorphan-HBr-bupropion-HCl; Dextromethorphan/bupropion; Dextromethorphan/bupropion modulated delivery tabletLatest Information Update: 10 Jun 2025
At a glance
- Originator ANTECIP BIOVENTURES
- Developer Axsome Therapeutics; Duke University
- Class Anti-inflammatories; Antidementias; Antidepressants; Behavioural disorder therapies; Morphinans; Propiophenones; Small molecules; Smoking cessation therapies
- Mechanism of Action Adrenergic receptor antagonists; Cytochrome P-450 CYP2D6 inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder
- Phase III Agitation
- Phase II Smoking withdrawal
Most Recent Events
- 25 Apr 2025 Axsome Therapeutics terminates the phase III long term extension trial in Agitation in US and Puerto Rico, due to the completion of the overall program objectives (NCT06736509)
- 03 Mar 2025 Axsome Therapeutics announced the intention to submit a New Drug Application (NDA) to the US FDA for Agitation in 3Q of 2025
- 10 Feb 2025 Axsome Therapeutics enters into a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to bupropion/dextromethorphan